Alan P. Venook, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses which biomarkers to order and when, the role of checkpoint inhibitors, and chemotherapy choices.
Lee N. Newcomer, MD, who recently retired as Senior Vice President for Oncology and Genetics at UnitedHealth Group, discusses lessons learned during his long career in managed care, where we are, and where we need to go.
April K.S. Salama, MD, of Duke Cancer Institute, talks about how to select systemic therapy for a patient with previously treated metastatic melanoma.
Anthony D. Elias, MD, of the University of Colorado Cancer Center, reviews promising experimental treatments, as well as PARP inhibitor therapy in TNBC, including the implications of newly approved olaparib for gBRCA-mutant breast cancer.
James L. Mohler, MD, of Roswell Park Cancer Institute, discusses personalized medicine, molecular risk stratification, and better androgen-deprivation therapy for men with prostate cancer.
William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses recent evidence on the efficacy, safety, and utility of HER2-targeted treatments in the adjuvant setting for early-stage and advanced breast cancers.
